Video-on-Demand Library

18 March 2024

Min-Hua Jen, Kate Ren, Andrew Thomson, Marcia Rueckbeil and Richard Sizelove

Randomised controlled trials (RCTs) have been the gold standard for the evaluation of efficacy and safety of medical interventions. However, investigators have incentives to look for alternative ways to obtain relevant comparative effect estimates more rapidly for healthcare decision makers. The EUnetHTA 21 methodological guidelines will be officially finalised late in 2024 and will impact the statistical approaches used to obtain these effect estimates. Indirect treatment comparisons (ITCs) for the joint clinical assessment (JCA) require the estimation of comparative effectiveness via non-randomised designs.    Statisticians must be prepared for the changes this guidance will require. Indirect treatment comparisons should be considered a fundamental tool in the pharmaceutical statistician's toolbox, alongside other commonly used statistical techniques in the industry.  This webinar aims to provide information on the purpose and methods for ITC. The speakers will review and compare different approaches for ITC in both anchored and unanchored case. Both drug regulatory and reimbursement body’s views on using ITC will be discussed. The speakers will offer insights into issues such as marginal and conditional effect, unmeasured confounding and provide case studies to demonstrate the use of ITC methods in practice.  The event will be structured as two webinars, each of 3 hours. The first webinar will discuss ITC for an anchored case. The second webinar will discuss ITC for an unanchored case. You do not have to attend both webinars, but we highly recommend you join both webinars to have a comprehensive understand of the topic in ITC.  

Part of Collection(s)


Upcoming Events

Latest Jobs